carthera.eu

Evaluation du site carthera.eu

Home - Carthera

 Généré le 09 Avril 2026 01:59

Vieilles statistiques? UPDATE !

Le score est de 61/100

Optimisation du contenu

Titre

Home - Carthera

Longueur : 15

Parfait, votre titre contient entre 10 et 70 caractères.

Description

Revolutionizing severe brain disease treatments

Longueur : 47

Idéalement, votre balise META description devrait contenir entre 70 et 160 caractères (espaces compris). Utilisez cet outil gratuit pour calculer la longueur du texte.

Mots-clefs

Très mauvais. Nous n'avons pas trouvé de balise META keywords sur votre page. Utilisez ce générateur gratuit de balises META en ligne pour créer des mots-clés.

Propriétés Open Graph

Bien, cette page profite des balises META Open Graph.

Propriété Contenu
locale en_US
locale:alternate fr_FR
type website
title Home - Carthera
description Revolutionizing severe brain disease treatments
url https://carthera.eu/
site_name Carthera

Niveaux de titre

H1 H2 H3 H4 H5 H6
1 5 73 0 0 0
  • [H1] GLIOBLASTOMA and CNS DISEASES Revolutionizingbrain treatments
  • [H2] CARTHERA In a few figures
  • [H2] NO BRAIN DISEASE beyond reach
  • [H2] CLINICAL NEED AND SOLUTION Overcoming the BBB
  • [H2] Our latest news
  • [H2] AGENDA Our events
  • [H3] Our team
  • [H3] Indications
  • [H3] Strategy
  • [H3] Our ambition
  • [H3] Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel
  • [H3] Repeated blood−brain barrier opening using low-intensity pulsed ultrasound mitigates amyloid pathology
  • [H3] Carthera receives EMA expert panel endorsement for Orphan Medical Device status of SonoCloud® system
  • [H3] Carthera reaches recruitment milestone in SONOBIRD pivotal trial for recurrent glioblastoma
  • [H3] Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood–Brain Barrier Opening
  • [H3] Effects of blood-brain barrier opening using ultrasound on tauopathies: A systematic review
  • [H3] Using ultrasound technology to open the blood brain barrier
  • [H3] Endothelial response to blood-brain barrier disruption in the human brain
  • [H3] Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound- mediated BBB opening: A novel combinatorial immunotherapy regimen for gliomas
  • [H3] Effect of ultrasound-mediated blood-spinal cord barrier opening on survival and motor function in females in an ALS mouse model
  • [H3] Carthera receives positive opinion from French High Authority for Health on Innovation Funding scheme to treat patients with recurrent glioblastoma
  • [H3] Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas
  • [H3] Carthera receives Orphan Drug Designation (ODD) from US and EU authorities for carboplatin in malignant glioma
  • [H3] Paclitaxel and Carboplatin in Combination with Low-Intensity Pulsed Ultrasound for Glioblastoma
  • [H3] Carthera partners with Agenus and Northwestern University for phase 2a trial combining SonoCloud-9® with checkpoint inhibitors to treat glioblastoma
  • [H3] Positive results from phase I/II clinical trial of SonoCloud-9® in treatment of glioblastoma published in Nature Communications
  • [H3] Repeated blood–brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial
  • [H3] Carthera enrolls first patient in pivotal trial of SonoCloud-9® device for treatment of recurrent glioblastoma
  • [H3] Series B round reaches €42M
  • [H3] Carthera signs strategic collaboration with Accord Healthcare
  • [H3] Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase I clinical trial
  • [H3] Evaluating drug delivery enhancement following ultrasound treatment
  • [H3] Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas
  • [H3] Carthera appoints Dr. Oern Stuge as chairman of board of directors
  • [H3] Childhood Brain Tumors: A Review of Strategies to Translate CNS Drug Delivery to Clinical Trials
  • [H3] Low-Intensity Pulsed Ultrasound-Mediated Blood-Brain Barrier Opening Increases Anti-Programmed Death-Ligand 1 Delivery and Efficacy in Gl261 Mouse Model
  • [H3] Carthera closes €37.5M Series B funding round
  • [H3] Promising results from SonoCloud-9 clinical trial in combination with nab-paclitaxel have been published in Lancet Oncology
  • [H3] Carthera announces positive outcome of End-of-Phase 2 meeting with FDA for SonoCloud-9 system for treatment of recurrent glioblastoma
  • [H3] Carthera receives FDA Breakthrough Device Designation for SonoCloud-9 system
  • [H3] Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease
  • [H3] Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models
  • [H3] SonoCloud® technology enhances the efficacy of immunotherapies for the treatment of brain tumor.
  • [H3] Launch of a new phase I/IIclinical trial in collaboration with Northwestern University in Chicago
  • [H3] Carthera receive €2M grant and €10.5M equity from the European Innovation Council
  • [H3] First patient enrolled in new clinical trial for SonoCloud technology in melanoma
  • [H3] Ultrasound-induced blood-brain barrier disruption for the treatment of gliomas and other primary CNS tumors
  • [H3] Blood–brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors
  • [H3] Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations
  • [H3] Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives
  • [H3] Study of the means to characterize the opening of the blood-brain barrier induced by an implantable ultrasound device
  • [H3] Strategic collaboration with US-based company Lantheus
  • [H3] Latest data from the SonoCloud-9 clinical study presented at SNO on November 20-24, 2019
  • [H3] Collaboration with KIYATEC in effort to bring personalized medicine to patients stricken by brain cancer
  • [H3] FDA approval to launch a Phase 1/2a trial in glioblastoma
  • [H3] Pascal Girin, new chairman of the Board of Directors
  • [H3] Temporary blood–brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma
  • [H3] Publishing of complete results of Phase I/IIa clinical trial using the SonoCloud-1 ultrasound implant
  • [H3] Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma
  • [H3] Blood-brain barrier disruption in humans using an implantable ultrasound device: quantification with MR images and correlation with local acoustic pressure
  • [H3] ANSM approval to launch a phase I-II clinical trial for the SonoCloud-9 device
  • [H3] Closing of a €9M ($10.3M) Series B funding round
  • [H3] Potentialisation des chimiothérapies dans le traitement du glioblastome : étude des transporteurs ABC et ouverture de la barrière hémato-encéphalique par ultrasons
  • [H3] Capacitive Micro-machined Ultrasound Transducers for Interstitial High Intensity Ultrasound Therapies
  • [H3] Blood-brain barrier, cytotoxic chemotherapies and glioblastoma
  • [H3] Safe long-term repeated disruption of the blood-brain barrier using an implantable ultrasound device: a multiparametric study in a primate mod
  • [H3] Clinical trial of blood-brain barrier disruptionby pulsed ultrasound
  • [H3] Enhanced brain distribution ofcarboplatin ina primate model afterblood–brain barrier disruption using an implantable ultrasound device
  • [H3] Ultrasound-induced opening of the blood-brain barrier to enhance temozolomide and irinotecan delivery: an experimental study in rabbits
  • [H3] A multi-element interstitial ultrasound applicator for the thermaltherapy of brain tumors
  • [H3] Opening of the blood-brain barrier with an unfocused ultrasound device in rabbits
  • [H3] 30th Annual Meeting of SNO, Society for Neuro-Oncology
  • [H3] 20th Annual Meeting of EANO, European Association of Neuro-Oncology
  • [H3] Congress of Neurological Surgeons (CNS)
  • [H3] Annual Congress of EANS, European Association of Neurosurgical societies
  • [H3] 24th Annual International Symposium on Therapeutic Ultrasound (ISTU)
  • [H3] Annual meeting of ANOCEF, Association des Neuro-oncologues d'Expression Française
  • [H3] Brain Tumor Biotech Day
  • [H3] NMN symposium, Nuclear medecine and Neuro-Oncology

Images

Nous avons trouvé 102 image(s) sur cette page Web.

71 attribut(s) alt sont vides ou manquants. Ajouter un texte alternatif permet aux moteurs de recherche de mieux comprendre le contenu de vos images.

Ratio texte/HTML

Ratio : 31%

Idéal! le ratio de cette page texte/HTML est entre 25 et 70 pour cent.

Flash

Parfait, aucun contenu FLASH n'a été détecté sur cette page.

Iframe

Dommage, vous avez des Iframes sur vos pages Web, cela signifie que son contenu ne peut pas être indexé par les moteurs de recherche.

Réécriture d'URLs

Bien. Vos liens sont optimisés!

Tiret bas dans les URLs

Parfait! Aucuns soulignements détectés dans vos URLs.

Liens dans la page

Nous avons trouvé un total de 10 lien(s) dont 0 lien(s) vers des fichiers

Texte d'ancre Type Juice
About Us Interne Passing Juice
Our Solutions Interne Passing Juice
Research & Development Interne Passing Juice
Our News Interne Passing Juice
Legal Mentions & Disclaimer Interne Passing Juice
Privacy Policy Interne Passing Juice
U.S. Expanded Access Policy Interne Passing Juice
Sitemap Interne Passing Juice
Contact (EN) Interne Passing Juice
Kookline Externe Passing Juice

Mots-clefs

Nuage de mots-clefs

more brain publication barrier read ultrasound request glioblastoma scientific carthera

Cohérence des mots-clefs

Mot-clef Contenu Titre Mots-clefs Description Niveaux de titre
publication 69
scientific 34
carthera 32
request 32
brain 32

Ergonomie

Url

Domaine : carthera.eu

Longueur : 11

Favicon

Génial, votre site web dispose d'un favicon.

Imprimabilité

Aucun style CSS pour optimiser l'impression n'a pu être trouvé.

Langue

Bien. Votre langue est : en.

Dublin Core

Cette page ne profite pas des métadonnées Dublin Core.

Document

Doctype

HTML 5

Encodage

Parfait. Votre charset est UTF-8.

Validité W3C

Erreurs : 0

Avertissements : 0

E-mail confidentialité

Attention! Au moins une adresse e-mail a été trouvée en texte clair. Utilisez une protection anti-spam gratuite pour cacher vos e-mails aux spammeurs.

HTML obsolètes

Génial! Nous n'avons pas trouvé de balises HTML obsolètes dans votre code.

Astuces vitesse

Excellent, votre site n'utilise pas de tableaux imbriqués.
Mauvais, votre site web utilise des styles css inline.
Génial, votre site web contient peu de fichiers CSS.
Parfait, votre site web contient peu de fichiers javascript.
Parfait : votre site tire parti de gzip.

Mobile

Optimisation mobile

Icône Apple
Méta tags viewport
Contenu FLASH

Optimisation

Sitemap XML

Votre site web dispose d’une sitemap XML, ce qui est optimal.

https://carthera.eu/sitemap_index.xml

Robots.txt

https://carthera.eu/robots.txt

Votre site dispose d’un fichier robots.txt, ce qui est optimal.

Mesures d'audience

Manquant

Nous n'avons trouvé aucun outil d'analytics sur ce site.

Un outil de mesure d'audience vous permet d'analyser l’activité des visiteurs sur votre site. Vous devriez installer au moins un outil Analytics. Il est souvent utile d’en rajouter un second, afin de confirmer les résultats du premier.

PageSpeed Insights

Dispositif
Les catégories

Free SEO Testing Tool

Free SEO Testing Tool est un outil gratuit de référencement qui vous aidera à analyser vos pages web